Michael Cilento

Medical Oncologist & PhD candidate. Passionate about precision oncology and #ProstateCancer research 🧬 @SAiGENCI / @uniofadelaide

[Michael Cilento @drcilento]

Proud to co-author this Review with Prof @ChrisSweens1, whose leadership and dedication continue to advance care for people affected by prostate cancer. Published in @NatRevClinOncol. #prostatecancer #pcsm

@LisaButler5 @drlouiseemmett

[NatureRevClinOncol @NatRevClinOncol]

New online! Personalized intensification of treatment for hormone-sensitive prostate cancer https://t.co/otfACAP8Zb

[Anis Hamid @anis_a_hamid]

Decipher is consistent across trials in IDing group benefiting from intensification. @ChrisSweens1 presents data from ENZAMET - great collab btw @Decipher_VCYT @ANZUPtrials and participating centers. More molecular data coming from ENZAMET - see our germline profiling poster tmrw

[Advanced Prostate Cancer Consensus Conference @APCCC_Lugano]

Personalized intensification of treatment for hormone-sensitive prostate cancer

https://t.co/S98ko2tEWm

Hormone-sensitive #ProstateCancer (HSPC) management has advanced beyond androgen-deprivation therapy (ADT) alone, now incorporating androgen receptor pathway inhibitors (ARPIs), docetaxel, and radiotherapy based on disease state and biology.

Modern PSMA PET imaging detects metastases earlier than conventional scans, redefining patient subgroups and influencing decisions such as when to use chemotherapy or radiotherapy. Treatment is increasingly personalized, guided by prior local therapy, PSA dynamics, disease volume, and imaging findings, with ARPI–ADT doublets forming the backbone for metastatic disease. Attention to toxicity from long-term testosterone suppression is crucial, while emerging biomarker-driven therapies—including ^177Lu-PSMA-617, AKT inhibitors, and PARP inhibitors—are poised to further refine care.

@drcilento
@LisaButler5
@drlouiseemmett
@ChrisSweens1

@OncoAlert 🚨
@Silke_Gillessen
@AOmlin
@weoncologists

[Michael Cilento @drcilento]

Thanks for sharing @OscarTahuahua!

[Oscar Tahuahua @OscarTahuahua]

Personalized intensification of treatment for hormone-sensitive prostate cancer @NatRevClinOncol

Goal: hit cancer harder, earlier & smarter with biology, risk & PSMA-PET. ADT+ARPI = backbone for most pts.

Docetaxel for de novo high-volume.
Prostate RT: survival boost in low-volume.
Enzalutamide±ADT: best for high-risk BCR.
🌟PSMA-PET reshapes staging, EMBARK showed M1 in 46% despite negative CT/Bone scan (~30-40% higher detection)

Next discussions: integrating 177Lu-PSMA, AKT & PARP inhibitors after +ve trials with biomarkers as the key to pt selection ✅

Really nice review
https://t.co/1sAL8AcJRo @OncoAlert

[Uromigos @Uromigos]

The second #ProstateCancer session at #UromigosLive 2025 was a discussion about the approach to mHSPC, building on ADT+ARPI and debating the inclusion of a third agent including docetaxel, PARPi, radioligand or AKT inhibition. https://t.co/6Zy9duoviM for full videos with slides. @OncoAlert

[Arun Azad @AzadOncology]

1/ 🚨 Pleased to share that our latest manuscript is out now in @EUplatinum!

Baseline and on-treatment #ctDNA biomarkers in men with advanced #ProstateCancer treated with #LuPSMA.

https://t.co/koAm8SgnK9

Thanks to @LouiseKostos Heidi Fettke @PeterMacCC

[JAMA Oncology @JAMAOnc]

Immune checkpoint inhibitors can improve survival in solid organ transplant recipients with advanced cancers, but survival rates remain limited.

#TSANZConf @TSANZ_txsoc

https://t.co/L80IACCN4e

[Annals of Oncology @Annals_Oncology]

📢#ASCO25 concomitant publication: BRCA1/2 and homologous recombination repair alterations in high- and low-volume metastatic HSPC: prevalence and impact on outcomes @Dolmos77 @Dav_Lorente @igginel @nromerolaorden @casilda_llacer @cdanicas @BerUrologia
https://t.co/0qc58N0MhV

[Michael Hofman @DrMHofman]

Stunning research from @EdmondMKwan on ctDNA in theranostics:
🧬Low ctDNA predicts better response with ¹⁷⁷Lu-PSMA-617 vs. cabazitaxel chemotherapy
⚠️PTEN alterations linked to worse outcomes on cabazitaxel
🧪ATM defects tied to favorable PSMA-617 results
🩻PET quantitative biomarkers (SUVmean) are additive

🌟We identify new candidate biomarkers for ¹⁷⁷Lu–PSMA-617 selection and ultimately expand the mCRPC predictive biomarker repertoire

Online at @NatureMedicine
https://t.co/WvEQS4ZWol

@ANZUPtrials #TheraP @MovemberAUS @PCFA
Support by @PCF_Science Challenge Award
@ResearchWyatt @AzadOncology @Prof_IanD

[Ryan Nipp, MD, MPH, MBA, FASCO @RyanNipp]

Time to Treatment Initiation for the 30 Most Prevalent #Cancer Types: Trends and Predictors of Change.

https://t.co/7OmusjbMqI

@ASCO @JCO_ASCO @JCOOP_ASCO
#CancerTreatment #CancerResearch #CancerCare

[South Australian immunoGENomics Cancer Institute @SAiGENCI]

Great to see a full-house for @SAiGENCI's third Annual Public Lecture on Tuesday night featuring @Lab_Jenkins and @marazeissig speaking on the topic of "Fighting cancer from within: your immune system may hold the key" https://t.co/cyM2wx9iOT @UniofAdelaide

[Michael Cilento @drcilento]

https://t.co/9JP2r844qw

[ANZUP @ANZUPtrials]

Congrats @ANZUPtrials #ENZAp study positive OS & QoL results presented by @drlouiseemmett @ASCSO #GU25 & published @TheLancet. @MovemberAUS @CancerAustralia @AstellasEurope #ARTnet @StVincentClinic @RoyMorganAus @Novartis @mimsoftware @GenesisCare @ANSTO @TrialsCentre @Prof_IanD

[Cancer Research Communications @CRC_AACR]

Recently published:
#ClonalHematopoiesis of Indeterminate Potential (CHIP) & Its Association with Treatment Outcomes & Adverse Events in Patients with Solid Tumours. https://t.co/BAXcbt8GS3
@jonathanloree @jaypsv @rob_vanner @PancreasBC @BCCancer #openaccess

[EllisLab_ @EllisLab_]

Latest journey in #prostatecancer cell plasticity. Team effort @ChrisSweens1 @kat_morel @BeatrizGerFalc

Work stems from previous @ChrisSweens1 investigations in NFkB regulation by tristetraprolin (TTP; gene ZFP36), and generation of the NFkBi dimethylaminoparthenolide (DMAPT)

[South Australian immunoGENomics Cancer Institute @SAiGENCI]

Announcing further @SAiGENCI grant success with @LanKhuyenNguyen, @marazeissig and @drcilento awarded funding from @tourdecure_aus to further their work in prostate and pancreatic cancers. Read more at https://t.co/TPopr4penj @UniofAdelaide 👏👊🎉

[South Australian immunoGENomics Cancer Institute @SAiGENCI]

Congratulating @SAiGENCI legends @LisaButler5 and @Mohamed_I_Saad on their NHMRC Ideas Grant success! See project details at https://t.co/Bk4Cw7Z7it @UniofAdelaide 👏👊🎉

[Michael Cilento @drcilento]

Thrilled to receive this generous support from @SA_genomics & @BioplatformsAus for our project! Looking forward to taking the next steps with an amazing team including @LGMartelotto @LisaButler5 @ChrisSweens1 ,Marten Snel & Kristen Feher! ⭐️🧬🔬

[South Australian Genomics Centre (SAGC) @SA_genomics]

🌟A huge thank you to our amazing speakers & everyone who joined us for our special Seminar on Wed to announce the Awardees of the SA #Multiomics Framework Initiative @BioplatformsAus & celebrate their groundbreaking projects! 👏 We can't wait to see the impact of your work! 🚀🔬

[Michael Cilento @drcilento]

🌟Support SAiGENCI Cancer Research and help fund groundbreaking science! Plus, you can double your impact through matched giving on Giving Day! Let's make a lasting impact together. 💪🌍 #UoAGivingDay #UAMakeHistory Donate now!
https://t.co/YVwoLUGVkg

[South Australian immunoGENomics Cancer Institute @SAiGENCI]

Nice work Team SAiGENCI raising over $1,300 for cancer research at today's @TheLongestTable morning tea. Not too late to donate at https://t.co/pv9uRiL1jW Together let's #forkcancer! @hosp_research @UniofAdelaide 👊